Martha M. Lemnge

Dr. Martha Moshi Lemnge is Chief Research Scientist and Director of Tanga Research Centre. Dr. Lemnge is a holder of BSc (Biochemistry)of the University of Zambia and PhD  of the University of Copenhagen, Denmark. In 1978 she joined the former Malaria Research Laboratory (now Malaria Control Centre), Lusaka, Zambia where she worked until 1987 when she joined the Tanzania National Institute for Medical Research (NIMR). Since then she has continued to work on various aspects of malaria at NIMR as a research scientist.
From October 1998 to August 2005 she was the Director of Amani Research Centre. When most of the research activities were moved from Amani to Tanga in September 2005, she continued to hold the position of  Director at the newly operationalised Tanga Research Centre. She also holds the scientific post of Chief Research Scientist.
Dr Lemnge’s main area of research is malaria chemotherapy and immunology. Her research is in clinical and biomedical research at both hospital and community levels. Together with colleagues from Bugando and KCMC, they have been working with the National Malaria Control Programme in monitoring antimalarial drug resistance at 4 of the 8 sentinel sites in Tanzania. Data employed in changing antimalarial drug policy twice in Tanzania was provided by these trials. Similarly, data that was used to review antimalarial drug policy in Zanzibar was provided by Dr. Lemnge. She has received research grants from several donors (DANIDA/ENRECA, MRC (UK), MVI, MCTA, AMANET, BMGF, GMP, Wellcome Trust, EC, CCAA/IDRC) for research on different aspects of malaria and capacity building.
Together with colleagues from University of Copenhagen she developed and published a new HPLC method for simultaneous determination of dapsone/pyrimethamine in human plasma and whole blood. Jointly, with the same group, Dr. Lemnge was able to demonstrate that insecticide treated nets could reduce antimalarial drug resistance as evidenced by reduced mutations in the dhfr gene of Plasmodium falciparum among Tanzanian children treated with sulphadoxine-pyrimethamine.
Dr Lemnge is a member of several networks/consortia related to her research in malaria. Some of them include: (i) IPTi Consortium Executive Committee (2004-2006); (ii) AMANET Scientific Coordinating Committee (2005-2007); (ii) GSK/MVI Clinical Trial Partnership Committee (Sept 2005 to Nov 2006); (iii) MVI Communications Working Group (Nov 2006 to date); (iv) MCTA  (May 2006 to date); (v) MalariaGEN (June 2006 to date); (vi) Member, Malaria Node Committee, EACCR, EDCTP (Effective Jan 2010).
Dr. Lemnge has supervised five PhD students. She has also been an external examiner to 2 PhD and 2 MSc dissertations. Dr. Lemnge has over 80 publications in refereed Journals. Her publication record goes back to 1988 when she published her first research work done during her days in Zambia.